HOPA 2020: High But Not Normal BMI in Chronic-Phase CML Is Linked to Improved Outcomes With Dasatinib vs Imatinib
BMI may be a predictive factor of treatment response in patients with chronic-phase CML.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.